View all News & Blog posts »
View all projects »
View all publications »
Interactive data visualizations of antibiotic use and resistance in North America and Europe
ICF International and the London School of Hygiene and Tropical Medicine. Independent Evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm). Multi-Country Independent Evaluation Report: Preliminary Report of July 18, 2012.
The Global Fund to Fight AIDS,
Tuberculosis and Malaria and the World Health Organization. Meeting Report: Consultation on the Economics and Financing of Universal Access to
Parasitological Confirmation of Malaria. May 31-June 1 2010. (Appendix 1, Appendix 2)
CDDEP Febrile Illness Consultation Reports
CDDEP. Economics and Financing of Febrile Illness
RDTs: Report of Consultation 1. 20
October 2011, Seattle. CDDEP.
CDDEP. Economics and Financing of Febrile Illness RDTs: Report of Consultation 2. 23–24 February 2012, Washington, D.C.
At the end of 2012, AMFm completes a pilot phase—phase
1—in seven countries: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania and
Uganda. The board of the Global Fund to Fight AIDS, TB and Malaria takes up
AMFm’s future at a meeting in November, with input from the independent
evaluation that they commissioned, which was carried out by ICF International
and the London School of Hygiene and Tropical Medicine. At the same time, a
working group established by the boards of the Global Fund and the Roll Back
Malaria Partnership is engaged in analyses to inform the discussion of
subsidized artemisinin-combination therapies (ACTs) and the expanded use of
rapid diagnostic tests (RDTs) for malaria. With declines in malaria prevalence
in some countries and the expanded availability of diagnostics to easily
distinguish malaria from other febrile illnesses comes the imperative to align
fever management with the new realities.
This meeting connects these issues: 17 September will be devoted to AMFm and future scenarios, and 18 September to the developing febrile illness management paradigm. The principal investigators of the AMFm independent evaluation, the analysts working on the transition path from AMFm Phase 1, members of the Global Fund and Roll Back Malaria advisory committee, and many experts in febrile illnesses—including malaria and pneumonia—will present their work and views at this meeting, before Global Fund board decisions are taken in November.